Novartis, Elan Sue IPC Over Generic Focalin XR
Elan's suit, filed in the U.S. District Court for the District of Delaware, targets IPC, Intellipharmaceutics Ltd. and Par Pharmaceuticals Inc. Novartis and Celgene Corp., meanwhile, filed suit in the U.S. District Court for the District of New Jersey, naming IPC as the sole defendant.
Focalin XR is manufactured for...
Already a subscriber? Click here to login